期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤疫苗研究进展及应用现状 被引量：2

Research Progress and Application Status of Tumor Vaccines
下载PDF
导出
摘要 肿瘤疫苗主要包括肿瘤细胞疫苗、肿瘤多肽疫苗、肿瘤基因疫苗和肿瘤树突状细胞疫苗等,通过接种引起细胞免疫,激发人体自身的天然抗肿瘤反应达到防治肿瘤的目的。本文从机体抗肿瘤免疫机制的阐述出发,对各类肿瘤疫苗的作用特点、研究进展及应用现状作一综述。 Tumor vaccines mainly include tumor-cell vaccines,tumor polypeptide vaccines,tumor gene vaccines and tumor dendritic cell vaccines.which can causes cell immunity by vaccination as well as arousing natural anti-tumor response in the body to achieve the tumor treatment and prevention.This reviews all kinds of tumor vaccine about its effective characteistcs, study progress and application status based on anti-tumor immunity of the body.
作者 谢晓原 陈俊辉
机构地区 汕头大学医学院第一附属医院
出处 《医学综述》 2007年第12期896-898,共3页 Medical Recapitulate
关键词 肿瘤 疫苗 免疫治疗 Tumor Vaccines Immunotherapy
分类号 R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Salgia R,Lynch T,Skarin A,et al.Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma[J].J Clin Oncol,2003,21(4):624-630.
  • 2Nemunaitis J,Sterman D,Jablons D,et al.Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer[J].J Natl Cancer Inst,2004,96(4):326-331.
  • 3Antonia SJ,Seigne J,Diaz J,et al.Phase I trial of a B7.1(CD80) gene modified autologous tumor cell vaccine in combination with svstemic interleukin-2 in patients with metastatic renal cell carcinoma[J].J Urol,2002,167(5):1995-2000.
  • 4Rosenberg SA,Yang JC,Schwartzentruber DJ,et al.Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma[J].Nat Med,1998,4(3):321-327.
  • 5Rivoltini L,Squarcina P,Loftus DJ,et al.A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8 T cell with enhanced functional characteristics:implication for more effective immunotherapy[J].Cancer Res,1999,59(2):301-306.
  • 6Brinckerhoff LH,Kalashnikov VV,Thompson LW,et al.Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide:implications for peptide vaceines[J].Int J Cancer,1999,83(3):326-334.
  • 7Li Z,Qiao Y,Liu B,et al.Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia[J].Clin Cancer Res.2005,11(12):4460-4468.
  • 8Speiser DE,Lienard D,Rufer N,et al.Rapid and strong human CD8 T cell responses to vaccination with peptide,IFA,and CpG oligodeoxynucleotide 7909[J].J Clin Invest,2005,115(3):739-746.
  • 9Gulley JL,Arlen PM,Bastian A,et al.Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer[J].Clin Cancer Res,2005,11(9):3353-3362.
  • 10Kalat M,Kupcu Z,Schuller S,et al.In vivo plasmid electroporation induces tumor antigen-specific CD8 T-cell responses and delays tumor growth in a syngeneic mouse melanoma model[J].Cancer Res,2002,62(19):5489-5494.

二级参考文献24

  • 1马文学 余海 金洪传 见:杨晓 邓初夏 叶鑫生主编.跨膜型超抗原葡萄球菌肠毒素A基因的克隆及表达载体的构建[A].见:杨晓,邓初夏,叶鑫生主编.基因打靶和功能基因组学[C].北京:军事医学科学出版社,2001.p170-176.
  • 2White J, Herman A, Pullen AM, et al. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell, 1989, 56 (1): 27-35.
  • 3Janeway CA. Autoimmune disease. immunotherapy by peptides? Nature,1989, 341 (6242): 482-483.
  • 4Dohlsten M, Sundstedt A, Bjorklund M, et al. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer,1993, 54(3): 482-488.
  • 5Dohlsten M, Abrahmsen L, Bjork P, et al. Monoclonal antibody-superantigen fusion protein: tumor specific agents for T-cell-based tumor therapy.Proc Natl Acad Sci USA, 1994, 91 (19): 8945-8949.
  • 6Rosendahl A, Hansson J, Sundstedt A, et al. Immime response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer,1996, 68 (1): 109-113.
  • 7Hansson J, Ohlsson L, Persson R, et al. Genetically engineered superantigeas as tolerable antitumor agents. Proc Natl Acad Sci USA, 1997, 94(6):2489-2494.
  • 8Takemura S, Kudo T, Asano R, et al .A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.Cancer Immunol Immunother,2002, 51(1): 33-44.
  • 9Mondal TK,Bhatta D,Biswas S,et al.Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes,cytokines,and nitric oxide.Biochem Biophys Res Commun, 2002, 290(4) : 1336-1342.
  • 10Rosendahl A,Kristensson K,Hansson J,et al. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol, 1998, 160(11): 5309-5313.

共引文献5

同被引文献39

  • 1王洪武.肺癌疫苗的研究现状[J].临床肿瘤学杂志,2005,10(3):323-326. 被引量：2
  • 2闻玉梅.治疗性疫苗的研究进展[J].中华微生物学和免疫学杂志,1996,16(3):155-158. 被引量：24
  • 3Nemunaitis J,Jahan T,Ross H,et al.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther,2006,13(6):555-562.
  • 4Nemunaitis J.GVAX(GM-CSF gene modified tumor vaccine)in advanced stage non-small cell lung cancer[J].J Control Release,2003,91(1/2):225-231.
  • 5Nemunaitis J,Sterman D,Jablons D,et al.Granulocyte-macro-phage colony-stimulating factor gene-modified autologous tumor vaccines in non-small cell lung cancer[J].J Natl Cancer Inst,2004,96(4):326-331.
  • 6Nemunaitis J,Dillman RO,Schwarzenberger PO,et al.Phase II study of belagenpumatucel-L,a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4721-4730.
  • 7Atanackovic D,Altorki NK,Stockert E,et al.Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients[J].J Immunol,2004,172(5):3289-3296.
  • 8Ramos TC,Vinageras EN,Ferrer MC,et al.Treatment of NSCLC patients with an EGF-based cancer vaccine:report of a Phase I trial[J].Cancer Biol Ther,2006,5(2):145-149.
  • 9González G,Crombet T,Neninger E,et al.Therapeutic vaccination with epidermal growth factor(EGF)in advanced lung cancer:analysis of pooled data from three clinical trials[J].Hum Vaccin,2007,3(1):8-13.
  • 10Nakajima H,Kawasaki K,Oka Y,et al.WTl peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WTl peptide vaccination alone[J].Cancer Immunol Immunother,2004,53(7):617-624.

引证文献2

二级引证文献6

医学综述
2007年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部